17 January 2019

NICE, Level 1, City Tower, Piccadilly Plaza, Manchester, M1 4BT

Final agenda 

The meeting will start promptly at 10:00 and is expected to finish at approximately 12:00

Please note that this agenda is subject to change before the meeting.

  1. Welcome and introduction to format of meeting – Part 2 only (closed session)
  2. Apologies – Part 2 only (closed session)
  3. Any other business – Part 2 only (closed session)
  4. Appraisal of Atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer [ID1210]

    The Committee for Medicinal Products for Human Use (at the European Medicines Agency) has not yet given its regulatory opinion for Atezolizumab in combination for treating advanced non-squamous non-small-cell lung cancer and as a consequence this discussion will take place in a part 2 session (part 2 sessions are closed to public observers).

    • 4.1 Declarations of interest - Part 2 only (closed session)
      4.2 Introduction by the Chair, Professor Gary McVeigh Part 2 only (closed session)
      4.3 Presentation by the lead team Part 2 only (closed session)
      4.4 Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) - Part 2 only (closed session)

To print an agenda, please right click and select 'Print' from the menu.

Date, time and venue of next meeting

The next meeting will take place on Thursday 14 February 2019 at 10:00, at NICE, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT 

Please note all timings are approximate.